Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 9;15(11):1767–1772. doi: 10.1016/j.jtho.2020.06.019

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Severe urticarial rash in addition to the elevation of DD in a patient with SCC of the lung treated with Ipi/Nivo after becoming infected with SARS-CoV-2 (ipi 1 mg/kg every 6 wks plus Nivo 3 mg/kg every 15 days). (C-red) contact with a patient infected with COVID-19; (A) beginning of the cutaneous manifestations; (B) onset painful polyarthritis; (C) normal chest radiograph; (D) normal chest CT-scan; (E) skin biopsy; (F) current joint and skin status. COVID-19, coronavirus 2019; CR, complete response; CT, computed tomography; DD, D-dimer; EKG, electrocardiogram; HCQ, hydroxychloroquine.; Ipi, ipilimumab; Nivo, nivolumab; PR, partial response; RT-PCR, reverse transcriptase–polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome–coronavirus-2; SC, subcutaneous; SCC, squamous cell carcinoma.